CanBas: Financial results briefing materials for the 2nd quarter of the fiscal year ending 2025/6

JPXFeb 20 10:30 · Announcements

CanBas: Half Year Report - Term 26 (2024/07/01 - 2025/06/30)

EDINETFeb 13 14:54 · Announcements

CanBas: Summary of financial results for the 2nd quarter (interim period) of the fiscal year ending 2025/6 [Japanese GAAP] (unconsolidated)

JPXFeb 13 14:40 · Announcements

Stocks that moved the previous day part 2: NF HD, Liberta, Muromachi Chemical ETC.

Stock Name <Code> 7-day Closing Price ⇒ Change from Previous Day IFOREX <9517> 739 -20 There is a sense of completion despite rapid rebounds. K&O Energy Group <1663> 3720 -60 Selling pressure is gathering on perovskite-related stocks on the 7th. Kawasaki Kisen Kaisha <9107> 2229 -62.56 Profit-taking sales are dominant in the strong-moving marine shipping stocks. Renova <9519> 768 -29 As a renewable energy-related stock, strong movements were noticeable up to the 6th. ACCESS <4813> 906 -27.

Fisco JapanJan 8 06:32

Stocks that moved or were traded in the first half of the session.

*Fujitsu General Ltd. <6755> 2769 +496 Paloma is conducting a TOB to fully become a subsidiary.* KOKUSAI ELECTRIC <6525> 2414.5 +241.5 due to an increase in sales at Hon Hai Precision, leading to a Buy on Semiconductors-related stocks.* Tokyo Electron Ltd. Unsponsored ADR <8035> 26925 +2565, related stocks are favored due to the rise in U.S. semiconductor stocks.* Japan Micronics <6871> 4295 +405, buying also directed towards smaller Semiconductors-related companies.* Asteria <

Fisco JapanJan 7 12:25

Canvas rebounds, patent examination granted by the U.S. Patent Office for immune system anticancer drug candidate compounds.

Canvas <4575.T> rebounded, momentarily reaching a high of 28 yen at 915 yen. After the close on the 6th, the company announced that it had received a patent decision from the U.S. Patent Office regarding its immune system anti-cancer drug candidate compound "CBT005", which was regarded as significant news. The company considers this new patent acquisition as a result of the knowledge accumulated in the field of cancer immunology and its experience in peptide drug creation and plans to advance "CBT005" to preclinical trials in the medium term, thus creating a promising development pipeline for the future.

Kabushiki ShimbunJan 7 09:44